CORE--PHARMACOLOGY

描述：（申请人描述）药理学核心实验室 为所有三个项目提供分析支持，但 特别是0143项目，发育性化疗项目。 上一 应用，氯喹喔啉磺酰胺（CQS）的药理学研究， 维甲酸、苯乙酸、苯丁酸和9-氨基喜树碱 完成了。除此之外，分析实验室还支持 几项药物开发赠款，包括I期和II期的U 01合同 临床试验 预计这笔赠款将需要大约 每年1500个样本分析。 药理学核心实验室的具体目标是：（1）提供 用于分析治疗药物的集中药理学实验室 生物样品中;（2）表征药代动力学， I期和II期研究中新药的药效学 3个项目的研究;（3）调查人口 靶向药物包括PDX、脱氧上皮酮B和 通过有限的采样时间表， 本项目;（4）为临床前和 新药剂和组合的制剂研究。

DESCRIPTION: (Applicant's Description) The pharmacology core laboratory provides analytical support for all three projects in this grant, but especially Project 0143, the Developmental Chemotherapy Project. In the previous application, the pharmacology studies of chloroquinoxaline sulfonamide (CQS), retinoic acids, phenylacetic acied, phenylbutyric acid and 9-aminocamptothecin were completed. In addition to this grant, the analytical laboratory supports several drug development grants, including U01 contracts for phase I and II clinical trials. It is expected that this grant will require approximately 1500 sample analyses per year. The specific aims for the pharmacology core laboratory will be: (1) to provide a centralized pharmacology laboratory for the analysis of therapeutic agents in biological samples; (2) to characterize the pharmacokinetics and pharmacodynamics of new agents under investigation in Phase I and Phase II studies by each of the 3 projects; (3) to investigate the population pharmacokinetics of target agents including PDX, desoxyepithilone B and pyroxamide through limited sampling schedules in Phase II trials conducted in this project; and (4) to provide pharmacology support for preclinical and formulation studies of novel agents and combinations.